February 17, 2026 – Medtronic plc proclaims monetary outcomes for the third quarter (Q3) of fiscal 12 months 2026 (FY26) ended January 23, 2026.
Key highlights of the third quarter
- Income of $9.0 billion, up 8.7% as reported and 6.0% organically, 50 foundation factors larger than Q3 expectations
- GAAP diluted earnings per share of $0.89; non-GAAP diluted earnings per share of $1.36, three cents above the midpoint of Q3 steering
- The corporate reiterates natural income development and EPS steering for FY26
- Cardiac Ablation Options gross sales elevated by 80%, of which 137% within the US, because of the Pulsed Subject Ablation (PFA) portfolio
- Obtained CE Mark for Sphere-360™ and initiated US pivotal trial
- Obtained US FDA approval for Hugo™ robot-assisted surgical procedure; first instances accomplished this month
- Obtained US FDA clearance for the Stealth AXiS™ Surgical System for backbone procedures
- Diabetes gross sales elevated by 8.3% because of robust figures in worldwide markets
- Execution of the M&A technique with two main transactions within the quarter: CathWorks in coronary and renal denervation and Anteris in structural coronary heart
Proceed studying